Study of multifunctional anti-AD ligands: design, synthesis, X-ray crystal structure and biological evaluation of diosmetin derivatives
Molecular Diversity · 2025
DOI: 10.1007/s11030-024-10913-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Diversity, 2025. Verfasst von Aihong Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China. Hauptthemen laut MEDLINE: Cholinesterase Inhibitors, Drug Design, Flavonoids, Alzheimer Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
The development of anti-AD drugs has attracted much attention as the number of AD patients is increasing year by year. Five diosmetin derivatives (1-5) were designed and synthesized by introducing carbamate groups. The crystal structure of 1 was analyzed by X-ray diffraction, which showed a large conjugated coplanar structure and might be favorable for the insertion into the Aβ folding. Meanwhile, in vitro experiments were carried out to investigate the anticholinesterase activity, metal chelating property, antioxidant activity, and anti-Aβ aggregation ability of 1-5. The results showed that 1-5 had good cholinesterase inhibitory activities. Compound 4 showed the highest inhibitory activities against butyrylcholinesterase (IC50 = 0.0760 μM). Further kinetic experiments and molecular docking studies showed that 4 could bind well to butyrylcholinesterase. The molecular dynamics simulations also signified that compared with diosmetin, 4 could reduce the flexibility of the butyrylcholinesterase protein skeleton to a greater extent, and thus had a better inhibitory effect. In addition, 1-5 could selectively chelate copper ions and all of them had good antioxidant activity as well as anti-Aβ aggregation ability. Among them, 4 had the strongest activity to inhibit Cu2+-induced Aβ aggregation (51.09%) and had low cytotoxicity. In addition, in vivo ROS activity assay (Caenorhabditis elegans) showed that 4 had the ability to scavenge ROS. Besides, the in vivo Aβ aggregation assay showed that 4 could reduce Aβ aggregation. In conclusion, 4 has the potential to be developed into a multifunctional anti-AD drug.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
- Tianjin Key Laboratory of Therapeutic Substance of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China.
- School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China. shenr2016@126.com.
- Tianjin Key Laboratory of Therapeutic Substance of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China. shenr2016@126.com.
- School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China. xiaodikou2013@163.com.
- Tianjin Key Laboratory of Therapeutic Substance of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China. xiaodikou2013@163.com.
Zitieren
APA
Yang, A., Yi, X., Zhang, H., Chen, Q., Shen, R., & Kou, X. (2025). Study of multifunctional anti-AD ligands: design, synthesis, X-ray crystal structure and biological evaluation of diosmetin derivatives. Molecular Diversity. https://doi.org/10.1007/s11030-024-10913-w
Vancouver
Yang A, Yi X, Zhang H, Chen Q, Shen R, Kou X. Study of multifunctional anti-AD ligands: design, synthesis, X-ray crystal structure and biological evaluation of diosmetin derivatives. Molecular Diversity. 2025. doi:10.1007/s11030-024-10913-w
BibTeX
@article{Yang2025,
author = {Yang, Aihong and Yi, Xiaoyue and Zhang, Hongwei and Chen, Quanzhen and Shen, Rui and Kou, Xiaodi},
title = {Study of multifunctional anti-AD ligands: design, synthesis, X-ray crystal structure and biological evaluation of diosmetin derivatives},
journal = {Molecular Diversity},
year = {2025},
doi = {10.1007/s11030-024-10913-w}
}
EUVIMED